Basic | |
---|---|
Market Cap | $1.27M |
Price | $0.06 |
52 Week Range | 0.001-1.43 |
Beta | 3.05 |
Margins | |
Gross Profit Margin | 0.00% |
Operating Profit Margin | 0.00% |
Net Profit Margin | 0.00% |
Valuation (TTM) | |
P/E Ratio | -0.20 |
Price to Sales Ratio | 0.00 |
Price to Book Ratio | 0.57 |
PEG Ratio | -0.01 |
Biotechnology
Healthcare
57
2021-11-11T00:00:00.000Z
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
254 244 5739
1717 Main Street, Dallas, TX, 75201, US
0001851657